Amanta Healthcare IPO Listing Update

Great start in the market! On September 9, Amanta Healthcare Limited's shares had a good start on the Indian stock market. They listed at ₹135 per share on the NSE, which was 7.14% more than the issue price of ₹126. The stock opened a little lower on the BSE, at ₹134 per share, but it was still up 6.35% on its first day.

The listing was very close to what the market expected, with a grey market premium (GMP) of ₹9 per share, which means the listing was probably around ₹135.

Information about the IPO and important subscription points

From September 1 to September 3, people could sign up for Amanta Healthcare's IPO, and a lot of people did. The issue was oversubscribed 82.61 times, which shows that there was a lot of interest from all types of investors.

54.98 times more retail investors signed up
Non-Institutional Investors (NIIs) signed up 209.42 times.
35.86 times as many people signed up as Qualified Institutional Buyers (QIBs)
With the sale of 1 crore new equity shares, the IPO raised ₹126 crore. The minimum lot for retail investors was 119 shares, which cost ₹14,994 to buy.

The company will use the money to set up new manufacturing lines at its facility in Hariyala, Kheda, Gujarat, such as a SteriPort line and a Small Volume Parenterals (SVP) line. The money will also be used for other business needs.

About Amanta Healthcare

Amanta Healthcare is a pharmaceutical company that makes sterile liquid solutions. It has been around since 1994. The company's main skill is making parenteral solutions using the most recent Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) methods.

It sells a variety of products, such as:

IV fluids
Dilutants
Eye drops
Products for taking care of your lungs
Eye drops, first aid supplies, and irrigation solutions
This strong product line helps Amanta Healthcare grow its presence in the healthcare industry, both in the US and around the world.

Disclaimer:

This information is only for informational purposes. These opinions are not advice on how to invest. Please talk to a qualified financial advisor before you invest.